Movalis

Package Leaflet: Information for the Patient

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

Movalis (Мовалис)

10 mg/ml (15 mg/1.5 ml), solution for injection
Meloxicam
Movalis and Мовалис are trade names for the same drug, written in Polish and Bulgarian.

Before using the medicine, the patient should carefully read the leaflet, as it contains important information.

• The patient should keep this leaflet to be able to read it again if necessary.
• In case of any doubts, the patient should consult a doctor or pharmacist.
• This medicine has been prescribed to a specific person. It should not be given to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of Contents of the Leaflet:

• 1. What is Movalis and what is it used for
• 2. Important information before using Movalis
• 3. How to use Movalis
• 4. Possible side effects
• 5. How to store Movalis
• 6. Contents of the pack and other information

1. What is Movalis and what is it used for

Movalis contains the active substance meloxicam. Meloxicam belongs to a group of non-steroidal anti-inflammatory drugs (NSAIDs) used to reduce inflammation and pain in joints and muscles.
Movalis solution for injection is intended for adults.
Movalis is used to treat exacerbations of:

• rheumatoid arthritis;
• ankylosing spondylitis, when the medicine cannot be given by other routes of administration.

2. Important information before using Movalis

When not to use Movalis

• If the patient is allergic to meloxicam or any of the other ingredients of this medicine (listed in section 6).
• In pregnant women in the last three months of pregnancy.
• In children and adolescents under 18 years of age.
• If the patient has experienced any of the following symptoms after taking aspirin or other non-steroidal anti-inflammatory drugs:
• wheezing, feeling of tightness in the chest, shortness of breath (asthma);
• nasal congestion due to swelling of the nasal mucosa (nasal polyps);

Page 1 of 10

• skin rash and/or hives;
• sudden swelling of the skin or mucous membranes, such as swelling around the eyes, face, lips, mouth, or throat, which may make breathing difficult (angioedema).
• If the patient has experienced:
• gastrointestinal bleeding or perforation;
• ulcerative disease or gastrointestinal bleeding (ulcer or bleeding that has occurred at least twice).
• If the patient has severe liver dysfunction.
• In non-dialyzed patients with severe renal impairment.
• If the patient has recently experienced cerebral bleeding (cerebral hemorrhage).
• If the patient has experienced any other bleeding.
• In patients treated with anticoagulants (due to the risk of hematoma).
• If the patient has severe heart failure.

If the patient is unsure whether any of the above points apply to them, they should consult their doctor.

Warnings and precautions

Before starting treatment with Movalis, the patient should discuss it with their doctor or pharmacist.

Warnings

Taking medicines like Movalis may be associated with a small increased risk of heart attack (myocardial infarction) or stroke. This risk increases with long-term use of high doses of the medicine. The patient should not exceed the recommended dose and duration of treatment (see section 3).
In case of heart problems, previous stroke, or suspected risk of these disorders, the patient should discuss their treatment with their doctor or pharmacist.
For example, if:

• the patient has high blood pressure (hypertension);
• the patient has high blood sugar (diabetes);
• the patient has high cholesterol (hypercholesterolemia);
• the patient smokes.

The patient should stop using Movalis immediately if they notice bleeding (causing black stools) or gastrointestinal ulceration (causing abdominal pain).
With the use of Movalis, potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported, initially appearing as red spots or round patches on the torso, often with central blisters. Additional symptoms that may be observed include ulcers in the mouth, throat, nose, genitals, and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may develop into generalized blisters or peeling of the skin. The highest risk of severe skin reactions occurs in the first few weeks of treatment. In patients who have developed Stevens-Johnson syndrome or toxic epidermal necrolysis while taking Movalis, meloxicam should not be restarted.
If a rash or the above symptoms occur, the patient should stop using Movalis and seek medical attention immediately, informing their doctor that they are taking this medicine.
Movalis is not recommended for the treatment of acute pain attacks.
Page 2 of 10
Movalis may mask the symptoms of infection (e.g., fever). If the patient suspects they have an infection, they should consult their doctor.

Precautions for use

Due to the need to modify treatment, the patient should consult their doctor before starting Movalis if:

• they have a history of esophagitis, gastritis, or any other gastrointestinal disease, such as Crohn's disease or ulcerative colitis;
• they have high blood pressure (hypertension);
• they are elderly;
• they have heart, liver, or kidney disease;
• they have high blood sugar (diabetes);
• they have decreased blood volume (hypovolemia), which may occur with significant blood loss or burns, surgery, or low fluid intake;
• they have high potassium levels in the blood, previously diagnosed by their doctor.

In these cases, the doctor will monitor the patient's progress.

Movalis and other medicines

Movalis may affect the action of other medicines, and other medicines may affect the action of Movalis.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
In particular, the patient should inform their doctor or pharmacist if they are taking any of the following medicines:

• other non-steroidal anti-inflammatory drugs (NSAIDs);
• potassium salts - used to treat low potassium levels in the blood;
• tacrolimus - used after organ transplants;
• trimethoprim - used to treat urinary tract infections;
• anticoagulants;
• medicines that dissolve blood clots (thrombolytic agents);
• medicines used to treat heart and kidney diseases;
• corticosteroids (e.g., used as anti-inflammatory or to treat allergic reactions);
• cyclosporine - used after organ transplants or in cases of severe skin diseases, rheumatoid arthritis, or nephrotic syndrome;
• deferazirox - used to treat iron overload after frequent blood transfusions;
• diuretics; The doctor may monitor kidney function when taking diuretics.
• medicines used to treat high blood pressure (e.g., beta-blockers);
• lithium - used to treat mental illnesses;
• selective serotonin reuptake inhibitors (SSRIs) - used to treat depression;
• methotrexate - used to treat cancer or severe uncontrolled skin diseases and active rheumatoid arthritis;
• pemetrexed - used to treat cancer;
• cholestyramine - used to reduce cholesterol levels;
• oral anti-diabetic drugs (sulfonylurea derivatives, nateglinide) - used to treat diabetes. The doctor should ensure regular monitoring of the patient's blood sugar levels for hypoglycemia.

Pregnancy, breastfeeding, and fertility

Page 3 of 10
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.

Pregnancy

If the patient becomes pregnant while using Movalis, they should inform their doctor.
During the first six months of pregnancy, the doctor may continue to prescribe Movalis if necessary.
During the last three months of pregnancy, Movalis should not be used, as it may have a serious effect on the fetus, especially on its cardiovascular and respiratory systems, and kidneys, even after a single dose.

Breastfeeding

This medicine is not recommended for use in breastfeeding women.

Fertility

This medicine may make it harder to get pregnant. The patient should inform their doctor if they plan to get pregnant or have problems getting pregnant.

Driving and using machines

Visual disturbances, including blurred vision, drowsiness, dizziness, or other central nervous system disorders may occur after using Movalis. If these symptoms occur, the patient should not drive or operate machinery.

Movalis contains sodium

The medicine contains less than 1 mmol (23 mg) of sodium per 1.5 ml ampoule, which means the medicine is considered "sodium-free".

3. How to use Movalis

Movalis is intended for intramuscular injection only. The medicine should only be administered by experienced medical personnel. The medicine is injected slowly, intramuscularly, usually in the buttock. If more than one injection is necessary, the medicine will be injected into the other buttock. If the patient has a hip prosthesis, the medicine will be administered on the other side of the body. If the patient feels severe pain during injection, the administration of the medicine should be stopped.
Dosage:One injection is given at the start of treatment. Treatment can be extended using a maximum of one injection for 2 to 3 days in exceptional cases (e.g., when tablets cannot be used).

Do not exceed the recommended maximum dose of 15 mg per day.

If any of the conditions listed in "Warnings and precautions" apply to the patient, the doctor may reduce the dose to 7.5 mg of meloxicam per day (half of a 1.5 ml ampoule).
Elderly patients
The recommended dose for elderly patients in long-term treatment of rheumatoid arthritis and ankylosing spondylitis is 7.5 mg per day (half of a 1.5 ml ampoule).
Patients at increased risk of side effects
For patients at increased risk of side effects, treatment should be started with a dose of 7.5 mg per day (half of a 1.5 ml ampoule).
Renal impairment
In dialyzed patients with severe renal impairment, the dose should not exceed 7.5 mg per day (half of a 1.5 ml ampoule).
Page 4 of 10
Dose reduction is not necessary in patients with mild or moderate renal impairment.
Hepatic impairment
Dose reduction is not necessary in patients with mild or moderate hepatic impairment.
Use in children and adolescents
Movalis should not be given to children and adolescents under 18 years of age.
If the patient thinks that the effect of Movalis is too strong or too weak, or if they do not feel any improvement after a few days, they should consult their doctor or pharmacist.

Overdose of Movalis

In case of overdose or suspected overdose of Movalis, the patient should immediately consult their doctor or go to the nearest hospital emergency department.

Symptoms of NSAID overdose are usually limited to:

• weakness (feeling of lack of energy);
• drowsiness;
• nausea and vomiting;
• abdominal pain (in the upper abdomen). These symptoms usually resolve after stopping Movalis. The patient may experience gastrointestinal bleeding.

Severe poisoning can lead to serious side effects of the medicine (see section 4):

• high blood pressure (hypertension);
• acute renal failure;
• liver dysfunction;
• shallow breathing or respiratory arrest (respiratory depression);
• loss of consciousness (coma);
• seizures (convulsions);
• circulatory collapse (cardiovascular collapse);
• cardiac arrest;
• immediate allergic reactions (hypersensitivity), including:
• fainting;
• shortness of breath;
• skin reactions.

Missed dose of Movalis

The patient should not take a double dose to make up for a missed dose. They should take the next dose at the scheduled time.
If the patient has any further doubts about using the medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Movalis can cause side effects, although not everybody gets them.
The patient should stop using Movalis and consult their doctor or the nearest hospital immediately if they experience:

• any allergic reactions (hypersensitivity), which may manifest as:
• skin reactions, such as itching (pruritus), blistering, and peeling of the skin, which can be life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis), soft tissue damage (mucosal lesions), or erythema multiforme (see section 2). Erythema multiforme is a severe allergic skin reaction causing spots, red or purple stripes or blisters on the skin. It can also occur on the lips, eyes, and other moist body parts.
• swelling of the skin or mucous membranes, such as swelling around the eyes, face, and lips, mouth, or throat, which may make breathing difficult, swelling of the feet and ankles (peripheral edema);
• shortness of breath or asthma attack;
• liver inflammation. This can cause symptoms such as:
• yellowing of the skin and eyes (jaundice);
• abdominal pain;
• loss of appetite.

Any symptoms of gastrointestinal disorders, in particular:

• bleeding (causing black stools);
• gastrointestinal ulceration (causing abdominal pain).

Gastrointestinal bleeding, ulcers, or perforation can sometimes be severe and potentially life-threatening, especially in elderly patients.
If the patient has previously experienced any gastrointestinal disorders due to long-term use of NSAIDs, they should immediately consult their doctor, especially if they are elderly. The doctor may monitor the patient's progress.
If Movalis causes visual disturbances, the patient should not drive or operate machinery.

General side effects of non-steroidal anti-inflammatory drugs (NSAIDs)

The use of some non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with a small increased risk of arterial thrombosis (arterial occlusion), such as myocardial infarction or stroke, especially with long-term use of high doses of the medicine.
NSAID treatment has been associated with reports of edema, hypertension, and heart failure.
The most commonly observed side effects are related to the gastrointestinal tract (stomach and intestine disorders):

• gastric or duodenal ulcer;
• perforation of the intestinal wall or gastrointestinal bleeding (sometimes fatal, especially in elderly patients).

The following side effects have been reported with NSAIDs:

• nausea (nausea) and vomiting;
• diarrhea;
• flatulence with gas discharge;
• constipation;
• indigestion (dyspepsia);
• abdominal pain;
• black stools due to gastrointestinal bleeding;
• bloody vomiting;
• mouth ulcers;
• exacerbation of inflammatory bowel disease (e.g., exacerbation of ulcerative colitis or Crohn's disease).

Gastritis has been observed less frequently.

Side effects of meloxicam - the active substance of Movalis

Very common: may occur in more than 1 in 10 people

• gastrointestinal disorders, such as indigestion (dyspepsia), nausea (nausea), vomiting, abdominal pain, constipation, flatulence, diarrhea.

Common: may occur in less than 1 in 10 people

• headache;
• thickening at the injection site, pain at the injection site.

Uncommon: may occur in less than 1 in 100 people

• dizziness (feeling of emptiness in the head);
• dizziness or feeling of spinning (vertigo);
• drowsiness (somnolence);
• anemia (reduced hemoglobin levels);
• high blood pressure (hypertension);
• flushing (temporary flushing of the face and neck);
• retention of sodium and water;
• high potassium levels (hyperkalemia). This can lead to symptoms such as:
• heart rhythm disorders;
• palpitations (feeling of heartbeat);
• muscle weakness.
• reflux (regurgitation of stomach contents into the esophagus);
• gastritis;
• gastrointestinal bleeding;
• mouth ulcers;
• immediate allergic reactions (hypersensitivity);
• itching (pruritus);
• skin rash;
• edema caused by fluid retention, including swelling of the feet and ankles (peripheral edema);
• sudden swelling of the skin or mucous membranes, such as swelling around the eyes, face, lips, mouth, or throat, which may make breathing difficult (angioedema);
• temporary liver function test abnormalities (e.g., increased liver enzyme activity or increased bilirubin levels). The doctor may detect these changes with a blood test;
• abnormal kidney function test results (e.g., increased creatinine or urea levels).

Rare: may occur in less than 1 in 1000 people

• mood disorders;
• nightmares;
• blood disorders, including:
• abnormal blood smear;
• reduced white blood cell count (leukopenia);
• reduced platelet count (thrombocytopenia).

Page 7 of 10
These side effects may increase the risk of infection and symptoms such as bruising or nosebleeds.

• ringing in the ears (tinnitus);
• feeling of heartbeat (palpitations);
• gastric or duodenal ulcer;
• esophagitis;
• asthma attacks (in patients allergic to aspirin or other NSAIDs);
• blistering or peeling of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis);
• hives;
• visual disturbances, including:
• blurred vision;
• conjunctivitis (inflammation of the eye or eyelids).
• colitis (inflammation of the colon).

Very rare: may occur in less than 1 in 10,000 people

• blistering skin reactions and erythema multiforme; Erythema multiforme is a severe allergic skin reaction causing spots, red or purple stripes or blisters on the skin. It can also occur on the lips, eyes, and other moist body parts.
• liver inflammation. This can cause symptoms such as:
• yellowing of the skin and eyes (jaundice);
• abdominal pain;
• loss of appetite.
• acute renal failure, especially in patients with risk factors such as heart disease, diabetes, or kidney disease;
• perforation of the intestinal wall.

Frequency not known: frequency cannot be estimated from available data

• confusion;
• disorientation;
• anaphylactic shock;
• shortness of breath and skin reactions (anaphylactic/anaphylactoid) rash caused by exposure to sunlight (photosensitivity reactions);
• heart failure reported with NSAID treatment;
• complete loss of certain types of white blood cells (agranulocytosis), especially in patients taking Movalis with other medicines that may have a suppressive or destructive effect on the bone marrow (myelotoxic drugs). This can cause:
• sudden fever;
• throat pain;
• infections;
• pancreatitis;
• infertility in women, delayed ovulation.

Side effects of non-steroidal anti-inflammatory drugs (NSAIDs) not yet reported with Movalis:

Acute renal failure due to changes in kidney structure:

• very rare cases of interstitial nephritis (tubulointerstitial nephritis);
• necrosis of some kidney cells (acute tubular necrosis or renal papillary necrosis);
• presence of protein in the urine (nephrotic syndrome with proteinuria).

Reporting side effects

If the patient experiences any side effects, including any not listed in the leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 (22) 49 21 301, fax: +48 (22) 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Movalis

The medicine should be stored out of sight and reach of children.
Movalis should not be used after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
The medicine should not be stored above 30°C. It should be protected from light.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.

6. Contents of the pack and other information

What Movalis contains

The active substance of Movalis is meloxicam. One ml of the solution contains 10 mg of meloxicam.
One ampoule (1.5 ml of solution) contains 15 mg of meloxicam in the form of an enol salt formed during the manufacturing process.
The other ingredients are: meglumine, glycofurol, poloxamer 188, sodium chloride, glycine, sodium hydroxide, water for injections.

What Movalis looks like and contents of the pack

Movalis is a yellowish-green solution.
Movalis is available in 2 ml glass ampoules containing 1.5 ml of solution.
Pack sizes: 1, 3, 5 ampoules.
Other uses of meloxicam:
Meloxicam is also available in:

• 7.5 mg tablets
• 15 mg tablets.

For more detailed information, the patient should contact the marketing authorization holder or parallel importer:

Marketing authorization holder in Bulgaria, the country of export:

Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany

Manufacturer:

Boehringer Ingelheim Espana, S.A., Prat de la Riba, 50, 08174 Sant Cugat del Valles (Barcelona), Spain
Page 9 of 10

Parallel importer:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Bulgarian marketing authorization number: 20020142

Parallel import authorization number: 348/12 Date of approval of the leaflet: 24.06.2022

[Information about the trademark]
Page 10 of 10